Abstract
BACKGROUND--The 30 minute and 24 hour post-inhalation urinary excretion of salbutamol represents the relative amount of drug deposited in the lungs and total systemic absorption, respectively. Using this method two metered dose inhalers used with a Volumatic (Allen and Hanburys Ltd, UK) large volume spacer have been compared. METHOD--Eleven healthy volunteers inhaled 4 x 100 micrograms salbutamol from either a generic salbutamol (Baker Norton, UK) or Ventolin (Allen and Hanburys Ltd, UK) metered dose inhaler with a Volumatic. The order of administration was randomised with a seven day washout period. Urine samples were collected for 0-30 minutes and then pooled up to 24 hours after inhalation. RESULTS--The mean (SD) urinary salbutamol excretion 30 minutes after inhalation with the metered dose inhalers used with the Volumatic was 22.22 (4.63) and 21.30 (5.91) micrograms for the Baker Norton and Ventolin respectively, with a mean difference (95% confidence interval (CI)) of 0.92 (-0.65 to 2.49) micrograms. Similar amounts were excreted up to 24 hours after the dose with a mean (SD) urinary excretion of 116.1 (24.3) micrograms and 114.8 (22.3) micrograms, respectively, and a mean difference (95% CI) of 1.22 (-20.39 to 22.84) micrograms. CONCLUSION--Inhalations from generic salbutamol (Baker Norton) and Ventolin metered dose inhalers with a Volumatic inhalation aid deliver similar amounts of drug to the lungs and the total systemic absorption from the two products is the same.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Borgström L., Newman S., Weisz A., Morén F. Pulmonary deposition of inhaled terbutaline: comparison of scanning gamma camera and urinary excretion methods. J Pharm Sci. 1992 Aug;81(8):753–755. doi: 10.1002/jps.2600810807. [DOI] [PubMed] [Google Scholar]
- Chrystyn H. Standards for bioequivalence of inhaled products. Clin Pharmacokinet. 1994 Jan;26(1):1–6. doi: 10.2165/00003088-199426010-00001. [DOI] [PubMed] [Google Scholar]
- Cronin S. Spacer design. Lancet. 1993 Nov 27;342(8883):1361–1362. doi: 10.1016/0140-6736(93)92269-y. [DOI] [PubMed] [Google Scholar]
- Cyr T. D., Graham S. J., Li K. Y., Lovering E. G. Low first-spray drug content in albuterol metered-dose inhalers. Pharm Res. 1991 May;8(5):658–660. doi: 10.1023/a:1015825311750. [DOI] [PubMed] [Google Scholar]
- Hindle M., Chrystyn H. Determination of the relative bioavailability of salbutamol to the lung following inhalation. Br J Clin Pharmacol. 1992 Oct;34(4):311–315. doi: 10.1111/j.1365-2125.1992.tb05921.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hindle M., Chrystyn H. Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices. Thorax. 1994 Jun;49(6):549–553. doi: 10.1136/thx.49.6.549. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hultquist C., Wollmer P., Eklundh G., Jonson B. Effect of inhaled terbutaline sulphate in relation to its deposition in the lungs. Pulm Pharmacol. 1992 Jun;5(2):127–132. doi: 10.1016/0952-0600(92)90030-k. [DOI] [PubMed] [Google Scholar]
- Wallin A., Sandström T., Rosenhall L., Melander B. Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma. Thorax. 1993 Jun;48(6):611–614. doi: 10.1136/thx.48.6.611. [DOI] [PMC free article] [PubMed] [Google Scholar]